PMID- 22943648
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20151119
IS  - 0253-3758 (Print)
IS  - 0253-3758 (Linking)
VI  - 40
IP  - 6
DP  - 2012 Jun
TI  - [Role of valsartan on myocardial Calpain I, calcineurin and 
      Ca/calmodulin-dependent protein kinase IIdelta expression of renovascular 
      hypertensive rats].
PG  - 511-5
AB  - OBJECTIVE: To determine the protein expression of Calpain I, mRNA and protein 
      expressions and activity of calcineurin, and the alternative splicing of 
      Ca/calmodulin-dependent protein kinase II (CaMKII) delta in the hypertrophic heart, 
      and to investigate the effect of angiotensin II type 1 receptor blocker valsartan 
      (Val) on cardiac hypertrophy and the level of Calpain I, calcineurin and CaMKIIdelta 
      in renovascular hypertensive rats model. METHODS: Rats were randomly divided into 
      sham-operated control (n=8), hypertension (n=8) and hypertension plus Val (n=8, 
      30 mgxkg(-1)x(-1)). The renovascular hypertension was induced by two kidney-one 
      clip methods in rats. The ratio of left ventricular weight to body weight was 
      measured, the mRNA expression of calcineurin and alternative splicing of CaMKIIdelta 
      were determined by RT-PCR, the protein expression of Calpain I and calcineurin 
      were measured by Western blot and the activity of calcineurin activity was 
      assayed by a specialized kit. RESULTS: Eight weeks after procedure, hypertension 
      rats developed significantly cardiac hypertrophy, and the protein expression of 
      Calpain I, mRNA and protein expression and the activity of calcineurin were 
      significantly increased compared sham-operated control rats (all P<0.01), the 
      mRNA expression of CaMKIIdeltaA and B increased, CaMKIIdeltaC mRNA decreased (P<0.01). 
      Treatment with valsartan effectively attenuated cardiac hypertrophy and reversed 
      hypertension induced changes on myocardial Calpain I, calcineurin and CaMKIIdelta. 
      CONCLUSION: Valsartan attenuates cardiac hypertrophy in renovascular hypertensive 
      rats, possibly through inhibiting Calpain I, calcineurin and CaMKIIdelta signaling 
      pathways.
FAU - Lu, Jin-ya
AU  - Lu JY
AD  - Department of Cardiology, Affiliated Hospital of Nantong University, Nantong 
      226001, China.
FAU - Zhu, Jian-hua
AU  - Zhu JH
FAU - Qin, Xiao-tong
AU  - Qin XT
FAU - Yu, Xiao-hong
AU  - Yu XH
FAU - Sheng, Hong-zhuan
AU  - Sheng HZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Zhonghua Xin Xue Guan Bing Za Zhi
JT  - Zhonghua xin xue guan bing za zhi
JID - 7910682
RN  - 0 (RNA, Messenger)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinase Type 2)
RN  - EC 3.1.3.16 (Calcineurin)
RN  - EC 3.4.22.- (Calpain)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Animals
MH  - Calcineurin/metabolism
MH  - Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism
MH  - Calpain/metabolism
MH  - Hypertension, Renovascular/drug therapy/*metabolism/pathology
MH  - Male
MH  - Myocardium/*metabolism/pathology
MH  - RNA, Messenger/genetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Signal Transduction
MH  - Tetrazoles/*pharmacology/therapeutic use
MH  - Valine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Valsartan
EDAT- 2012/09/05 06:00
MHDA- 2013/10/01 06:00
CRDT- 2012/09/05 06:00
PHST- 2012/09/05 06:00 [entrez]
PHST- 2012/09/05 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Jun;40(6):511-5.